SCHEMBL4852219

SCHEMBL4852219

CNc1nc(OC)c(NC(=O)c2ccc(Cc3cc([Si](C)(C)C)ccc3C)o2)c(OC)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNRHR P30968 10/20 0.59
FPR1 P21462 1/20 0.47
GPR183 P32249 1/20 0.47
GPR119 Q8TDV5 1/20 0.47
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
CYP2C9 P11712 2/20 0.36
CACNA1F O60840 1/20 0.36
CHRM4 P08173 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
CHRM1 P11229 1/20 0.36
DRD1 P21728 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4860579 0.92 GNRHR (0.54) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL5212006 0.87 GNRHR (0.58) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL4864364 0.84 GNRHR (0.55) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL4855058 0.84 GNRHR (0.55) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL4857385 0.83 GNRHR (0.58) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL4860057 0.83 GNRHR (0.66) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL5268218 0.82 GNRHR (0.57) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL4860360 0.80 GNRHR (0.47) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL5265665 0.80 GNRHR (0.55) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL4862906 0.78 GNRHR (0.47) GNRHRFPR1GPR183GPR119ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407649-B2 Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents PARADIGM THERAPEUTICS LTD (GB) 2008-08-05 US claimed
EP-1644385-B1 SILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-08-29 EP claimed
US-20070110708-A1 Silicon compounds and their use PARADIGM THERAPEUTICS LTD (GB) 2007-05-17 US claimed
US-7407649-B2 Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents PARADIGM THERAPEUTICS LTD (GB) 2008-08-05 US disclosed
EP-1644385-B1 SILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-08-29 EP disclosed
US-20070110708-A1 Silicon compounds and their use PARADIGM THERAPEUTICS LTD (GB) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070110708-A1 Silicon compounds and their use SOST, SMAD3, SMAD2 GNRHR 1621/4885FPR1 3685/4885GPR183 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.